Spero Therapeutics Inc (SPRO) - Total Liabilities
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has total liabilities worth $9.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Spero Therapeutics Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Spero Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Spero Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Spero Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moller Y Perez
SN:MOLLER
|
Chile | CL$251.47 Billion |
|
Grammer AG
XETRA:GMM
|
Germany | €1.43 Billion |
|
I Controls Inc
KO:039570
|
Korea | ₩178.69 Billion |
|
Nakamoto Inc.
NASDAQ:NAKA
|
USA | $216.35 Million |
|
The Andhra Sugars Limited
NSE:ANDHRSUGAR
|
India | Rs4.01 Billion |
|
Epileds Technologies Inc
TW:4956
|
Taiwan | NT$1.09 Billion |
|
Adriano Care SOCIMI SAU
MC:YADR
|
Spain | €132.09 Million |
|
Freelance.Com
PA:ALFRE
|
France | €364.30 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Spero Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Spero Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spero Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spero Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Spero Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.90 Million | -84.64% |
| 2024-12-31 | $64.42 Million | -14.67% |
| 2023-12-31 | $75.50 Million | +54.49% |
| 2022-12-31 | $48.87 Million | -40.97% |
| 2021-12-31 | $82.78 Million | +286.64% |
| 2020-12-31 | $21.41 Million | -32.09% |
| 2019-12-31 | $31.53 Million | +139.75% |
| 2018-12-31 | $13.15 Million | +54.32% |
| 2017-12-31 | $8.52 Million | +14.99% |
| 2016-12-31 | $7.41 Million | -0.30% |
| 2015-12-31 | $7.43 Million | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more